• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Unveils New Spinach® 1.2g Vapes and SOURZ by Spinach® Gummies Enhanced with Rare Cannabinoids

    4/22/25 8:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email

    TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc.'s (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") best-selling cannabis brand, Spinach®, is thrilled to introduce three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach® Fully Blasted flavors, infused with rare cannabinoids.

    The new lineup includes three new 1.2 gram vapes in the following formats:

    • Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio.
    • Peach Passionfruit Kush CBN (Indica): A dreamy, restful experience with a 1:10 CBN-to-THC ratio.
    • Strawberry Watermelon OG CBG (Hybrid): A blissful, relaxed high with a 1:10 CBG-to-THC ratio.



    Designed for consumers who prioritize both potency and added value, these vapes deliver 1,000mg of THC without compromising on the unique benefits of rare cannabinoids. Each product features winterized, distilled cannabis extract for purity, combined with terpene-rich flavors inspired by renowned cultivars. All Spinach® vapes are crafted with ceramic heaters, stainless steel components, and food-grade materials to ensure quality and a smooth experience.

    In addition to the Spinach® vape launch, Cronos is expanding its best-selling edible line, SOURZ by Spinach®, with the new Fully Blasted lineup with each package containing one 10mg THC gummy in bold, fruit-forward flavors:

    • Mango Lime: Tropical mango and tangy lime flavors with 10mg CBC and 10mg THC per gummy.
    • Peach Passionfruit: Peach and exotic passionfruit flavors with a balanced ratio of 10mg CBN and 10mg THC per gummy.
    • Strawberry Watermelon: Strawberry and refreshing watermelon flavors with 10mg CBG and 10mg THC per gummy.



    "We are thrilled to expand our Spinach® 1.2g vape and SOURZ by Spinach® Fully Blasted lineups with these innovative products that combine THC potency and the added benefits of rare cannabinoids. This new lineup will deliver what so many consumers are looking for: mouthwatering flavors, rare cannabinoid enhancers, and THC," said Mike Gorenstein, Chairman, President, and CEO of Cronos Group. "Cronos is committed to delivering exceptional cannabis experiences that meet evolving consumer preferences. Our goal is to continually innovate and provide our adult consumers with high-quality, enjoyable cannabis experiences. These new flavors and formulations reflect our dedication to quality, innovation, and giving consumers more reasons to choose Spinach®."



    The launch is backed by the brand's in-store trade marketing, with dedicated budtender education, digital placements, and enhanced point-of-purchase materials. For more information and availability, please visit: spinachcannabis.com.

    About Cronos Group Inc.



    Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

    Forward-looking Statements

            

    This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about product launches and innovations and the consumer experience with respect thereto; and the Company's intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

    Media Relations Contact:

    Emily Whalen

    [email protected]

    Investor Relations Contact:

    Harrison Aaron

    [email protected]



    Primary Logo

    Get the next $CRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    1/27/2022$5.54 → $3.24Underperform → Hold
    Jefferies
    More analyst ratings

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cronos Group Inc. to Hold Virtual 2025 Annual Meeting of Shareholders

      TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 Annual Meeting of Shareholders on Friday, June 20, 2025, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2025 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote. The Company's proxy statement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting is avail

      4/28/25 4:00:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

      TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

      4/24/25 8:00:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Unveils New Spinach® 1.2g Vapes and SOURZ by Spinach® Gummies Enhanced with Rare Cannabinoids

      TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc.'s (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") best-selling cannabis brand, Spinach®, is thrilled to introduce three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach® Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio.Peach Passionfruit Kush CBN (Indica): A dreamy, restful expe

      4/22/25 8:00:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cronos Group Inc.

      10-Q - Cronos Group Inc. (0001656472) (Filer)

      5/8/25 7:33:20 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Cronos Group Inc. (0001656472) (Filer)

      5/8/25 7:32:08 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Cronos Group Inc.

      DEFA14A - Cronos Group Inc. (0001656472) (Filer)

      4/25/25 4:35:16 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

      SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

      4/25/24 6:39:55 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

      SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

      12/19/22 8:47:03 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Financials

    Live finance-specific insights

    See more
    • Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

      TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

      4/24/25 8:00:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025

      TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

      2/24/25 4:45:45 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

      TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

      10/29/24 4:15:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Gorenstein Michael Ryan converted options into 3,000,000 shares and covered exercise/tax liability with 1,180,500 shares, increasing direct ownership by 17% to 12,508,772 units (SEC Form 4)

      4 - Cronos Group Inc. (0001656472) (Issuer)

      3/25/25 5:07:06 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Officer Shlimak Anna

      4 - Cronos Group Inc. (0001656472) (Issuer)

      3/21/25 5:06:37 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Weigensberg Arye converted options into 24,236 shares, increasing direct ownership by 26% to 117,337 units (SEC Form 4)

      4 - Cronos Group Inc. (0001656472) (Issuer)

      3/18/25 5:27:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Cronos Group with a new price target

      Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

      11/2/22 6:32:18 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Cronos Group from Hold to Buy

      7/28/22 9:01:16 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group upgraded by CIBC

      CIBC upgraded Cronos Group from Neutral to Sector Outperform

      5/11/22 7:33:42 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Cronos Appoints Anna Shlimak as Chief Financial Officer

      TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

      3/19/25 7:30:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

      TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g

      7/22/24 4:15:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders

      TORONTO, June 21, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held yesterday, June 20, 2024 (the "Meeting"), shareholders holding a total of 274,097,252 common shares of the Company voted in person or by proxy, representing 71.75% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 26, 2024 was elected as a director of the Company, with each director receiving in excess of 93.4% of the votes cast in favor of his or her election. The detailed results of the vote for the electio

      6/21/24 4:30:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care